DARZALEX FASPRO

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) · Janssen Biotech, Inc.

Drug timelines are a Plus or Pro feature.

22 regulatory and trial events tracked for DARZALEX FASPRO, covering 2020-05-01 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

See pricing